Brokerage firm Raymond James Downgrades its rating on ADMA Biologics Inc(NASDAQ:ADMA). The shares have been rated Market Perform. Previously, the analysts had a Strong Buy rating on the shares. The rating by Raymond James was issued on Aug 1, 2016.
In a different note, On Aug 1, 2016, Maxim Group said it Downgrades its rating on ADMA Biologics Inc. The shares have been rated ‘Hold’ by the firm.
ADMA Biologics Inc (ADMA) shares turned negative on Mondays trading session with the shares closing down -0.07 points or -1.11% at a volume of 1,11,238. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $6.54. The peak price level was also seen at $6.54 while the days lowest was $6.25. Finally the shares closed at $6.25. The 52-week high of the shares is $9.96 while the 52-week low is $4.15. According to the latest information available, the market cap of the company is $81 M.
Several Insider Transactions has been reported to the SEC. On May 5, 2016, James Mond (CSO/CMO) purchased 770 shares at $6.50 per share price.Also, On May 5, 2016, Brian Lenz (CFO) purchased 2,500 shares at $6.50 per share price.On May 5, 2016, Adam S Grossman (CEO) purchased 200,000 shares at $6.50 per share price, according to the Form-4 filing with the securities and exchange commission.
ADMA Biologics Inc. is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The Company’s lead product candidate RI-002 is intended for the treatment of primary immune deficiency disease (PIDD). RI-002 is an injectable immune globulin derived from human plasma with levels of naturally occurring polyclonal antibodies as well as levels of antibodies targeted to respiratory syncytial virus (RSV). The company’s RI-002 demonstrated Phase III results and attained its primary endpoint and preliminary analysis indicates that the treatment with RI-002 resulted in no serious bacterial infections (SBI’s) observed in study subjects during the trial.